Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.57 |
| ▸ | ECE1 | P42892 | 3/20 | 0.56 |
| ▸ | CPB1 | P15086 | 1/20 | 0.54 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.54 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.52 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.48 |
| ▸ | MME | P08473 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13324016 | 0.90 | MME (0.54) | ACEECE1MMECTSL | |
| SCHEMBL13324027 | 0.90 | CASP1 (0.55) | ACEECE1SIRT2SIRT1FOLH1 | |
| SCHEMBL13324023 | 0.88 | ACE (0.54) | ACECTSLCTSS | |
| SCHEMBL13324013 | 0.88 | ACE (0.61) | ACEECE1CPB1CPB2SIRT2 | |
| SCHEMBL13324028 | 0.88 | PSMB5 (0.47) | ACEECE1SIRT2SIRT1FOLH1 | |
| SCHEMBL7286230 | 0.85 | ACE (0.65) | ACEECE1CPB1CPB2SIRT2 | |
| SCHEMBL29791126 | 0.85 | ACE (0.65) | ACEECE1CPB1CPB2SIRT2 | |
| SCHEMBL13324026 | 0.85 | CTSK (0.49) | ECE1SIRT2SIRT1FOLH1MME | |
| SCHEMBL13324022 | 0.84 | CASP3 (0.55) | ACEECE1MMECTSLCTSS | |
| SCHEMBL13324029 | 0.84 | SIRT2 (0.49) | ECE1SIRT2SIRT1ITGB3FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723307-B2 | Amino acid derivatives and pharmaceutical uses thereof | ASTON UNIVERSITY (GB) | 2010-05-25 | — | — | US | disclosed |
| US-20080200511-A1 | Novel Compounds and Methods of Using the Same | ASTON UNIVERSITY (GB) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200511-A1 | Novel Compounds and Methods of Using the Same | F3, IL4I1, TPMT | ACE 3265/4885ECE1 3200/4885CPB1 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.